- Exopharm (EX1) has placed its shares in a trading halt as it gets ready to tap shareholders and investors for additional capital
- The biopharmaceutical company’s securities will remain halted from trading until April 20 at the latest
- No details have been released about the fundraising just yet, with an announcement expected before Tuesday
- Recently, EX1 celebrated after receiving positive results from its PLEXOVAL II phase one safety study
- The study involved a clinical trial where the company’s platelet-derived, exosome product Plexaris was tested on 11 patients
- Before today’s trading halt, shares in Exopharm were trading for 92 cents per share
Exopharm (EX1) has placed its shares in a trading halt as it gets ready to tap shareholders and investors for additional capital.
The biopharmaceutical company’s securities will remain halted from trading until April 20 at the latest, as it gears up to carry out a capital raise.
No details have been released about the fundraise endeavour, however an announcement on the fundraise is expected before Tuesday.
Recently, EX1 saw its share price surge after receiving positive results from its PLEXOVAL II phase one safety study.
The study involved a clinical trial where the company’s platelet-derived, exosome product Plexaris was tested on 11 enrolled patients.
Pleasingly, the study showed all of the patient’s wounds healed without any defects after being treated with Plexaris.
Additionally, all of the study’s participants remained healthy throughout the trial and during the 30-day follow-up period as well.
Before today’s trading halt, shares in Exopharm were trading for 92 cents per share at the close of market on Thursday.